Oral bioavailability and brain penetration of (-)-stepholidine, a tetrahydroprotoberberine agonist at dopamine D1 and antagonist at D2 receptors, in rats

被引:28
|
作者
Sun, Yan [1 ]
Dai, Jieyu [1 ]
Hu, Zheyi [1 ]
Du, Feifei [1 ]
Niu, Wei [1 ]
Wang, Fengqing [1 ]
Liu, Fei [1 ]
Jin, Guozhang [1 ]
Li, Chuan [1 ]
机构
[1] Chinese Acad Sci, Shanghai Inst Mat Med, SIBS, Shanghai Ctr DMPK Res, Shanghai 201203, Peoples R China
基金
中国国家自然科学基金;
关键词
(-)-stepholidine; CNS drug; enterohepatic barrier; blood-brain barrier; oral bioavailability; brain penetration; metabolic profiling; prodrug; L-STEPHOLIDINE; MASS-SPECTROMETRY; METABOLISM; DRUG; QUANTIFICATION; PLASMA; D1;
D O I
10.1111/j.1476-5381.2009.00393.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and purpose: (-)-Stepholidine has high affinity for dopamine D-1 and D-2 receptors. The aims of the present study were to examine the oral bioavailability and brain penetration of (-)-stepholidine and to gain understanding of mechanisms governing its transport across the enterohepatic barrier and the blood-brain barrier. Experimental approach: The pharmacokinetics of (-)-stepholidine was studied in rats and microdialysis was used to measure delivery to the brain. These studies were supported by biological measurement of unbound (-)-stepholidine. Membrane permeability was assessed using Caco-2 cell monolayers. Metabolite profiling of (-)-stepholidine in rat bile and plasma was performed. Finally, in vitro metabolic stability and metabolite profile of (-)-stepholidine were examined to compare species similarities and differences between rats and humans. Key results: Orally administered (-)-stepholidine was rapidly absorbed from the gastrointestinal tract; two plasma concentration peaks were seen, and the second peak might result from enterohepatic circulation. Due to extensive pre-systemic metabolism, the oral bioavailability of (-)-stepholidine was poor (< 2%). However, the compound was extensively transported across the blood-brain barrier, demonstrating an AUC (area under concentration-time curve) ratio of brain : plasma of similar to 0.7. (-)-Stepholidine showed good membrane permeability that was unaffected by P-glycoprotein and multidrug resistance-associated protein 2. In vitro (-)-stepholidine was metabolized predominantly by glucuronidation and sulphation in rats and humans, but oxidation of this substrate was very low. Conclusions and implications: Although (-)-stepholidine exhibits good brain penetration, future development efforts should aim at improving its oral bioavailability by protecting against pre-systemic glucuronidation or sulphation. In this regard, prodrug approaches may be useful.
引用
收藏
页码:1302 / 1312
页数:11
相关论文
共 50 条
  • [21] Role of dopamine D1 and D2 receptors in the micturition reflex in conscious rats
    Seki, S
    Igawa, Y
    Kaidoh, K
    Ishizuka, O
    Nishizawa, O
    Andersson, KE
    NEUROUROLOGY AND URODYNAMICS, 2001, 20 (01) : 105 - 113
  • [22] Iron deficiency decreases dopamine D1 and D2 receptors in rat brain
    Erikson, KM
    Jones, BC
    Hess, EJ
    Zhang, Q
    Beard, JL
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2001, 69 (3-4) : 409 - 418
  • [23] L-Stepholidine, a naturally occurring dopamine D1 receptor agonist and D2 receptor antagonist, attenuates heroin self-administration and cue-induced reinstatement in rats
    Yue, Kai
    Ma, Baomiao
    Chen, Lin
    Tian, Xiang
    Ru, Qin
    Gan, Yongping
    Wang, Daisong
    Jin, Guozhang
    Li, Chaoying
    NEUROREPORT, 2014, 25 (01) : 7 - 11
  • [24] AGONIST AND ANTAGONIST INTERACTIONS WITH D1 DOPAMINE-RECEPTORS - AGONIST-INDUCED MASKING OF D1 RECEPTORS DEPENDS ON INTRINSIC ACTIVITY
    OBOYLE, KM
    WADDINGTON, JL
    NEUROPHARMACOLOGY, 1992, 31 (02) : 177 - 183
  • [25] AUTORADIOGRAPHIC LOCALIZATION OF D1 AND D2 DOPAMINE-RECEPTORS IN THE HUMAN-BRAIN
    DEKEYSER, J
    CLAEYS, A
    DEBACKER, JP
    EBINGER, G
    ROELS, F
    VAUQUELIN, G
    NEUROSCIENCE LETTERS, 1988, 91 (02) : 142 - 147
  • [26] DOPAMINE D1 AND D2 RECEPTORS IN SPONTANEOUSLY HYPERTENSIVE RAT-BRAIN STRIATUM
    WATANABE, M
    TSURUTA, S
    INOUE, Y
    KINUYA, M
    OGAWA, K
    MAMIYA, G
    TATSUNUMA, T
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1989, 67 (12) : 1596 - 1597
  • [27] D1 AND D2 DOPAMINE-RECEPTORS IN THE RAT STRIATUM
    SZMIGIELSKI, A
    ZALEWSKAKASZUBSKA, J
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 183 (04) : 1418 - 1419
  • [28] Contribution of dopamine D1 and D2 receptors to amygdala activity
    Takahashi, H.
    Otsuka, T.
    Takano, H.
    Kodaka, F.
    Kikyo, H.
    Arakawa, R.
    Miyoshi, M.
    Okumura, M.
    Ito, H.
    Suhara, T.
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2009, 29 : S109 - S109
  • [29] Design and synthesis of D1 agonist/D2 antagonist for treatment of schizophrenia
    Giovanni, Andrew
    Roehr, Joachim
    Dwyer, Shannon
    Neuenschwander, Kent
    Scotese, Anthony
    Moorcroft, Neil D.
    Davis, Larry
    Gao, Zhongli
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (05) : 1498 - 1501
  • [30] D1 AND D2 DOPAMINE AGONIST SYNERGISM AND THE NUCLEUS-ACCUMBENS
    JACKSON, DM
    DREHER, K
    ROSS, SB
    TRENDS IN PHARMACOLOGICAL SCIENCES, 1987, 8 (11) : 419 - 420